1207618-05-0

Basic information

• Product Name: ethyl 1-[4-(5-ethyl-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate
• Synonyms: ethyl 1-[4-(5-ethyl-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate
• CAS NO: 1207618-05-0
• Molecular Weight: 360.477
• Mol File: 1207618-05-0.mol

Chemical Properties

• CAS DataBase Reference: ethyl 1-[4-(5-ethyl-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-[4-(5-ethyl-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate(1207618-05-0)
• EPA Substance Registry System: ethyl 1-[4-(5-ethyl-2-hydroxyphenyl)-1,3-thiazol-2-yl]-4-piperidinecarboxylate(1207618-05-0)

Safety Data

• Hazardous Substances Data: 1207618-05-0(Hazardous Substances Data)

Upstream product

• 675149-01-6 1-thiocarbamoyl-piperidine-4-carboxylic acid ethyl ester 
• 180154-50-1 C₁₀H₁₁BrO₂ 

Relevant articles and documents

THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.